BP
VRTX icon

Broadleaf Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Broadleaf Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,018
Closed -$2.68M – 83
2025
Q2 		$2.68M Buy
6,018
+22
+0.4% +$10.1K 0.59% 44
2025
Q1 		$2.91M Sell
5,996
-10,927
-65% -$5.09M 0.76% 42
2024
Q4 		$6.81M Sell
16,923
-201
-1% -$93.2K 1.59% 25
2024
Q3 		$7.96M Sell
17,124
-84
-0.5% -$40.4K 1.88% 22
2024
Q2 		$8.07M Sell
17,208
-114
-0.7% -$49.5K 1.95% 21
2024
Q1 		$7.24M Sell
17,322
-81
-0.5% -$34.2K 1.86% 21
2023
Q4 		$7.08M Sell
17,403
-62
-0.4% -$22.9K 2.08% 18
2023
Q3 		$6.07M Sell
17,465
-133
-0.8% -$46.5K 2.03% 25
2023
Q2 		$6.19M Buy
+17,598
New +$5.93M 2.02% 27
2021
Q4 		– Sell
-38,424
Closed -$6.97M – 76
2021
Q3 		$6.97M Buy
38,424
+1,595
+4% +$311K 2.31% 18
2021
Q2 		$7.43M Buy
36,829
+4,510
+14% +$943K 2.58% 10
2021
Q1 		$6.95M Buy
32,319
+1,434
+5% +$315K 2.62% 11
2020
Q4 		$7.3M Buy
30,885
+62
+0.2% +$14.2K 2.88% 10
2020
Q3 		$8.39M Buy
30,823
+4,925
+19% +$1.36M 3.7% 6
2020
Q2 		$7.52M Sell
25,898
-3,079
-11% -$835K 3.68% 8
2020
Q1 		$6.89M Sell
28,977
-198
-0.7% -$45.4K 4.44% 5
2019
Q4 		$6.39M Sell
29,175
-157
-0.5% -$31.8K 3.5% 8
2019
Q3 		$4.97M Buy
29,332
+6,104
+26% +$1.08M 3.11% 8
2019
Q2 		$4.26M Buy
23,228
+487
+2% +$85.1K 2.73% 13
2019
Q1 		$4.18M Buy
22,741
+1,009
+5% +$186K 2.92% 11
2018
Q4 		$3.6M Buy
21,732
+2,609
+14% +$452K 2.88% 11
2018
Q3 		$3.69M Sell
19,123
-246
-1% -$43.8K 2.47% 13
2018
Q2 		$3.29M Buy
+19,369
New +$3M 2.41% 17

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Broadleaf Partners's VRTX Position: Q3 2025 in Review

Broadleaf Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 6,018 shares — an estimated $2.68M sold.

Broadleaf Partners first reported a position in VRTX in Q2 2018 and held it in 23 quarters. The position peaked at $8.39M in Q3 2020. 1,520 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Broadleaf Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Broadleaf Partners sold 6,018 Vertex Pharmaceuticals shares in Q3 2025, an estimated $2.68M.
  • Broadleaf Partners first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 23 quarters.
  • Broadleaf Partners's Vertex Pharmaceuticals position peaked at $8.39M in Q3 2020.
  • 1,520 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Broadleaf Partners's 13F filing for Q3 2025, filed 13 Nov 2025.